口服与静脉抗生素治疗金黄色葡萄球菌菌血症或心内膜炎:随机对照试验的系统综述与荟萃分析
该系统综述检索截至2024年2月的四个数据库,仅纳入4项比较口服与静脉抗生素治疗金黄色葡萄球菌菌血症或心内膜炎的随机对照试验。荟萃分析显示两组治疗失败风险无差异(RR 0.99,95%CI 0.63-1.57,I²=0%),不良事件也无显著差异(RR 0.65,95%CI 0.07-5.94,I²=74%),但置信区间宽且异质性高。作者认为从静脉转为口服治疗可能在精心选择的部分患者中有效,但需更多随机试验才能常规推荐。
要点
- 口服与静脉抗生素治疗失败风险无差异(RR 0.99,95%CI 0.63-1.57,I²=0%)
- 不良事件无显著差异(RR 0.65,95%CI 0.07-5.94,I²=74%),但置信区间宽、异质性高
- 仅4项随机对照试验符合纳入标准,作者认为需更多随机试验才能常规推荐转为口服治疗
核心结论
- 在比较口服与静脉抗生素治疗金黄色葡萄球菌菌血症或心内膜炎的随机对照试验系统综述中,符合纳入标准的研究很少。
- 对这些研究的荟萃分析提示,从静脉转为口服治疗可能在精心选择的部分患者中有效。
- 在能够常规推荐转为口服治疗之前,还需要更多随机试验。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Library和Web of Science数据库,截至2024年2月。
- 纳入比较口服与静脉抗生素治疗金黄色葡萄球菌菌血症或心内膜炎并恰当报告各组结局的随机对照试验。
- 采用修订版Cochrane随机试验偏倚风险评估工具评估偏倚风险,用Cochran Q统计量和I²检验评估异质性,用随机效应模型荟萃分析汇总风险比(PROSPERO CRD42024481512)。
- 仅4项随机对照试验符合纳入荟萃分析的标准。
主要发现
- 在评估治疗失败的参与者中,口服治疗组与静脉治疗组之间无差异(RR 0.99,95%CI 0.63-1.57,I²=0%)。
- 口服治疗组与静脉治疗组之间不良事件无显著差异(RR 0.65,95%CI 0.07-5.94,I²=74%),但置信区间宽且异质性高。
临床怎么用
- 作者认为,从静脉转为口服治疗可能在精心选择的部分患者中有效。
- 作者认为,在能够常规推荐转为口服治疗之前,还需要更多随机试验。
局限性
- 仅4项随机对照试验符合纳入荟萃分析的标准,符合纳入标准的研究很少。
- 不良事件分析置信区间宽(95%CI 0.07-5.94)。
- 不良事件分析异质性高(I²=74%)。
- 作者指出在能够常规推荐转为口服治疗之前还需要更多随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted a systematic review of randomized, controlled trials (RCTs) to generate more precise estimates of the efficacy and safety of oral versus intravenous antibiotic therapy for Staphylococcus aureus bacteremia or endocarditis. METHODS: MEDLINE, Embase, the Cochrane Library, and Web of Science databases were searched through February 2024. RCTs were included if they compared oral versus intravenous antibiotic therapy for S. aureus bacteremia or endocarditis and appropriately reported outcomes for each group. Risk of bias was assessed using the revised Cochrane tool for assessing risk of bias in randomized trials. Heterogeneity between studies was evaluated with Cochran's Q-statistic and I2 test. Treatment effects were summarized with pooled risk ratios using a random effects model meta-analysis (PROSPERO CRD42024481512). RESULTS: Only four RCTs met criteria for inclusion in meta-analysis. Among participants assessed for treatment failure, there was no difference between oral and intravenous therapy groups (risk ratio [RR], 0.99; 95% confidence interval [CI], .63-1.57; I2 = 0%). There was also no significant difference in adverse events between oral and intravenous therapy groups (RR, 0.65; 95% CI, .07-5.94; I2 = 74%); however, the confidence interval was wide, and heterogeneity was high. CONCLUSIONS: In this systematic review of RCTs comparing oral with intravenous antibiotic therapy for S. aureus bacteremia or endocarditis, few studies met the eligibility criteria for inclusion. Meta-analysis of these studies suggests that transitioning from intravenous to oral therapy is likely effective in a subgroup of carefully selected patients. Additional randomized trials are necessary before transition to oral therapy can be routinely recommended.
引用
- Mourad A, Nwafo N, Skalla L, et al. Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin Infect Dis. 2025. PMID: 39290168. doi:10.1093/cid/ciae476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。